07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

Jubilant Life Sciences, Checkpoint Therapeutics deal

Jubilant’s Jubilant Biosys Ltd. subsidiary granted Checkpoint exclusive, worldwide rights to patents covering compounds that inhibit bromodomain containing 4 (BRD4) to treat cancer. Jubilant Biosys will receive $2 million up front and is eligible for...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

Checkpoint Therapeutics, TG Therapeutics deal

Checkpoint granted TG Therapeutics a worldwide sublicense to develop and commercialize bromodomain containing 4 (BRD4) inhibitors to treat hematological malignancies. Checkpoint will develop and commercialize the inhibitors to treat solid tumors. Checkpoint will receive a...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Jubilant Life Sciences, J&J deal

Johnson & Johnson's Janssen Pharmaceutica N.V. unit and Jubilant's Jubilant Biosys subsidiary expanded a 2011 deal to discover and develop neuroscience candidates. Under the expansion, Jubilant will develop and deliver preclinical candidates to Janssen in...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Jubilant Life Sciences, Mnemosyne deal

Jubilant's Jubilant Biosys Ltd. subsidiary and Mnemosyne partnered to discover preclinical candidates in the area of neuropsychiatric diseases, focusing on undisclosed subunit-selective NMDA receptor modulators (SNRMs) from Mnemosyne. Under the two-year deal, Mnemosyne has rights...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Endo, Jubilant Life Sciences deal

Jubilant's Jubilant Biosys Ltd. subsidiary received an undisclosed milestone payment after Endo selected a drug candidate targeting cancer for full development under the partners' 2009 deal. The undisclosed molecule is expected to enter clinical trials...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Jubilant Life Sciences, Norgine deal

Norgine partnered with Jubilant's Jubilant Biosys Ltd. subsidiary to discover and develop compounds to treat gastrointestinal diseases. Under the three-year deal, Jubilant will use its drug discovery technology to develop therapeutics through preclinical testing. Norgine...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Company News

Endo, Jubilant Life Sciences deal

Jubilant's Jubilant Biosys Ltd. subsidiary received an undisclosed milestone payment from Endo under a 2009 cancer drug discovery and development deal. This is the third milestone payment received under the deal. Terms were not disclosed...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Company News

Jubilant Life Sciences, AstraZeneca deal

Jubilant's Jubilant Biosys Ltd. subsidiary received a milestone payment from AstraZeneca under a 2009 drug discovery deal. The companies also announced that the partners amended the five-year deal to include cardiovascular and metabolic diseases as...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

Endo, Jubilant Life Sciences deal

Jubilant's Jubilant Biosys Ltd. subsidiary and Endo added additional targets to a 2009 cancer drug discovery and development deal after Jubilant met an undisclosed preclinical milestone. Jubilant will receive an undisclosed milestone payment. The lead...
07:00 , Jun 15, 2009 |  BC Week In Review  |  Company News

Endo Pharmaceuticals Inc., Jubilant Organosys deal

Jubilant's Jubilant Biosys Ltd. subsidiary will provide drug discovery and development services for Endo, which will own the resulting compounds. The three-year deal will focus initially on cancer. Jubilant will receive research funding and is...